35761-27-4

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-(S)-[N-CARBOBENZYLOXY]AMINO-3-AMINOPROPIONATE, HYDROCHLORIDE is used as a key building block for the synthesis of bioactive peptides containing DAP residues. Its role in the production of peptides such as bleomycins, edeines, and tuberactinomycins makes it a valuable component in the development of pharmaceuticals with potential therapeutic applications.
Used in Peptide Synthesis:
METHYL 2-(S)-[N-CARBOBENZYLOXY]AMINO-3-AMINOPROPIONATE, HYDROCHLORIDE is used as a crucial intermediate in the synthesis of peptides with DAP residues. Its presence in the synthesis process allows for the creation of complex peptide structures that can be further utilized in various applications, including drug development and research.
Used in Research and Development:
METHYL 2-(S)-[N-CARBOBENZYLOXY]AMINO-3-AMINOPROPIONATE, HYDROCHLORIDE is used as a research tool for studying the properties and potential applications of peptides containing DAP residues. Its role in the synthesis of bioactive peptides makes it an essential component in the ongoing research and development efforts aimed at discovering new therapeutic agents and understanding their mechanisms of action.

InChI:InChI=1/C12H16N2O4/c1-17-11(15)10(7-13)14-12(16)18-8-9-5-3-2-4-6-9/h2-6,10H,7-8,13H2,1H3,(H,14,16)/t10-/m0/s1

Upstream product

• 67-56-1 methanol 
• 35761-26-3 (S)-3-amino-2-(((benzyloxy)carbonyl)amino)propanoic acid 
• 2304-96-3 N-benzyloxycarbonyl-L-asparagine 
• 58457-98-0 methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]propanoate 
• 75760-11-1 (S)-methyl 3-amino-2-(((benzyloxy)carbonyl)amino)propanoate 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 90035-60-2 (L)-N-Z-azidoalanine methyl ester 
• 501-53-1 benzyl chloroformate 
• 1676-81-9 N-benzyloxycarbonyl-L-serine methyl ester 

Downstream Products

• 58457-98-0 methyl (2S)-2-{[(benzyloxy)carbonyl]amino}-3-[(tert-butoxycarbonyl)amino]propanoate 
• 211756-24-0 (S)-2-Benzyloxycarbonylamino-3-formylamino-propionic acid methyl ester 
• 130106-15-9 (S)-2-Benzyloxycarbonylamino-3-(4-chloro-butyrylamino)-propionic acid methyl ester 
• 211756-63-7 (S)-2-Benzyloxycarbonylamino-3-(3,3-dimethyl-ureido)-propionic acid methyl ester 
• 239789-53-8 methyl N²-benzyloxycarbonyl-N⁶-tert-butoxycarbonyl-2(S),6-diamino-4-azahexanoate 
• 578710-41-5 N^α-CBz-DAPA-N^β-(N,N'-di-Boc-β-Lys)-OMe 
• 223697-44-7 tert-butyl 4-[3-((3R)-3-{[((2S)-2-{[(benzyloxy)carbonyl]amino}-3-methoxy-3-oxopropyl)amino]carbonyl}-1-piperidinyl)-3-oxopropyl]-1-piperidinecarboxylate 
• 912369-05-2 methyl N-[(benzyloxy)carbonyl]-3-[(2-bromo-7-cyanothieno[3,2-c]pyridin-4-yl)amino]-L-alaninate 
• 1046536-09-7 C₁₇H₂₃ClN₂O₅ 
• 130106-16-0 (S)-2-benzyloxycarbonylamino-3-(2-oxo-pyrrolidin-1-yl)-propionic acid methyl ester hydrochloride 
• 211756-46-6 (S)-3-(Acetyl-methyl-amino)-2-benzyloxycarbonylamino-propionic acid methyl ester 
• 211756-64-8 [(S)-2-(3,3-Dimethyl-ureido)-1-hydroxymethyl-ethyl]-carbamic acid benzyl ester 
• 211756-61-5 ((S)-1-Hydroxymethyl-2-methanesulfonylamino-ethyl)-carbamic acid benzyl ester 
• 211756-47-7 [(S)-2-(Acetyl-methyl-amino)-1-hydroxymethyl-ethyl]-carbamic acid benzyl ester 

Relevant academic research and scientific papers

Total Synthesis and Biological Evaluation of Paenilamicins from the Honey Bee Pathogen Paenibacillus larvae

Paenilamicins are a group of complex polycationic peptide secondary metabolites with antibacterial and antifungal activities produced by the devastating honey bee brood pathogen Paenibacillus larvae causing the lethal brood disease American Foulbrood (AFB

Amide-derived lysine analogues as substrates and inhibitors of histone lysine methyltransferases and acetyltransferases

Histone lysine methyltransferases and acetyltransferases are two classes of epigenetic enzymes that play pivotal roles in human gene regulation. Although they both recognise and posttranslationally modify lysine residues in histone proteins, their difference in histone peptide-based substrates and inhibitors remains to be firmly established. Here, we have synthesised lysine mimics that posses an amide bond linker in the side chain, incorporated them into histone H3 tail peptides, and examined synthetic histone peptides as substrates and inhibitors for human lysine methyltransferases and acetyltransferases. This work demonstrates that histone lysine methyltransferases G9a and GLP do catalyse methylation of the most similar lysine mimic, whereas they typically do not tolerate more sterically demanding side chains. In contrast, histone lysine acetyltransferases GCN5 and PCAF do not catalyse acetylation of the same panel of lysine analogues. Our results also identify potent H3-based inhibitors of GLP methyltransferase, providing a basis for development of peptidomimetics for targeting KMT enzymes.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS

Compositions and methods for the treatment of fungal infections including compounds containing a pathogen pattern recognition receptor ligand and a β 1,3-glucan synthase inhibitor are disclosed. In particular, compounds containing a lipopeptide moiety and

Sulfate Encapsulation in Supramolecular Structures from L -Asparagine-Derived 2,5-Diketopiperazine Scaffolds: Anion Binding

We report a new sulfate receptor, anchored onto 2,5-diketopiperazine units, which results in the formation of two types of supramolecules; one in which the sulfate ion guest fits snugly into extended cavities and the other in which the guest is sandwiched between layers. In each case, the anion is held by six hydrogen bonds from the host. 1H NMR spectroscopic solution studies enabled the construction of Job plots, and calculation of stoichiometry and association constants. These findings are of possible significance in drug design and for construction of combinatorial libraries.

THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.

SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS

This invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

MODULATORS OF CELLULAR ADHESION

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).